Response to Comments: MolDX: Next-Generation Sequencing for Solid Tumors

This document is a response to public comments on the MolDX Next-Generation Sequencing (NGS) for Solid Tumors Local Coverage Determination (DL38067/L38501). It records the comment period (5/7/2019–6/21/2019) and the notice period start and effective dates (notice begins 12/26/2019; effective 2/10/2019). No specific clinical coverage criteria, limitations, or frequency limits are stated in this document; manual review of the referenced LCD (L38501/DL38067) is required to extract clinical policy rules.

"This document is a response to comments for the MolDX Next-Generation Sequencing for Solid Tumors LCD; comment period ran 5/7/2019–6/21/2019 and the notice period for L38501 begins 12/26/2019 with ..."

Sign up to see full coverage criteria, indications, and limitations.